Ultragenyx Pharmaceutical Inc (RARE) Expected to Post Quarterly Sales of $38.58 Million
Brokerages expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post sales of $38.58 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The lowest sales estimate is $300,000.00 and the highest is $136.44 million. The company is scheduled to issue its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $38.58 million for the current financial year, with estimates ranging from $2.60 million to $235.78 million. For the next fiscal year, analysts expect that the firm will post sales of $70.17 million per share, with estimates ranging from $16.58 million to $113.03 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The business had revenue of $2.41 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the previous year, the company posted ($1.75) earnings per share.
Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) traded up $0.21 during midday trading on Thursday, reaching $47.86. The company’s stock had a trading volume of 530,885 shares, compared to its average volume of 586,347. The firm has a market capitalization of $2,374.14, a P/E ratio of -6.73 and a beta of 1.89. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $91.35.
Several large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its position in Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 248 shares in the last quarter. California Public Employees Retirement System raised its position in Ultragenyx Pharmaceutical by 2.1% during the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock valued at $2,429,000 after acquiring an additional 800 shares in the last quarter. Swiss National Bank raised its position in Ultragenyx Pharmaceutical by 1.8% during the third quarter. Swiss National Bank now owns 67,252 shares of the biopharmaceutical company’s stock valued at $3,582,000 after acquiring an additional 1,200 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Ultragenyx Pharmaceutical by 6.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock valued at $1,237,000 after acquiring an additional 1,636 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Ultragenyx Pharmaceutical by 26.1% during the fourth quarter. Jane Street Group LLC now owns 8,821 shares of the biopharmaceutical company’s stock valued at $409,000 after acquiring an additional 1,828 shares in the last quarter. Hedge funds and other institutional investors own 85.01% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.